gms | German Medical Science

27th German Cancer Congress Berlin 2006

German Cancer Society (Frankfurt/M.)

22. - 26.03.2006, Berlin

Clinical significance of „reponse“ in neoadjuvant multimodality treatment concepts.

Meeting Abstract

Search Medline for

27. Deutscher Krebskongress. Berlin, 22.-26.03.2006. Düsseldorf, Köln: German Medical Science; 2006. DocIS034

The electronic version of this article is the complete one and can be found online at:

Published: March 20, 2006

© 2006 Fietkau.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License ( You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.



Neoadjuvant therapy is implemented in a variety of solid cancers for example breast cancer; rectal cancer or is under investigation for some entities for example oesophageal cancer, gastric cancer or pancreatic cancer. In nearly all investigations complete response of the tumours is associated with a better prognosis compared to patients with incomplete or no tumour regression. Nevertheless there are some open questions: -What is the best parameter for the evaluation of response for example theprimarytumour or the regional nodes? -Do we need special regression categories to evaluate the response of the tumour ? -Can we use the incidence of complete remissions as a surrogate parameter for long term survival? -Can we use the regression parameters to select or omit further therapies? For example surgery following complete reponse of neoadjuvant radiochemotherapy.